Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: MCBC regimen, Bu/Cy regimen.
- Who it may be relevant to
- Registry conditions: Acute Myeloid Leukemia. Basic parameters: up to 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This project is a prospective, multicenter, randomized controlled clinical study. The subjects were refractory / relapsed AML patients aged ≤ 60 years diagnosed by bone marrow cell morphology, immunology, genetics and therapeutic efficacy evaluation. The classical Bu / Cy scheme or MCBC scheme was used for pretreatment. The primary endpoint of the study was the 3-year recurrence-free survival rate after allogeneic hematopoietic stem cell transplantation, and the secondary endpoints were 3-year overall survival rate, recurrence rate, treatment-related mortality, and pretreatment-related toxicity.
Interventions
- Drug MCBC regimen
using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d - Drug Bu/Cy regimen
control group, the standard conditioning regimen Busulfan/Cyclophosphamide
Primary outcome measures
- Relapse Free Survival [Time frame: 3 year post-HSCT]
Secondary outcome measures (5)
- Overall Survival [Time frame: 3 year post-HSCT]
- cumulative incidence relapse rate [Time frame: 3 year post-HSCT]
- Non-relapse mortality [Time frame: 3 year post-HSCT]
- toxicity of conditioning regimen [Time frame: 24w post-HSCT]
- Immune reconstitution post-HSCT [Time frame: 24w post-HSCT]
Eligibility criteria
Inclusion criteria
- Refractory / relapsed AML.
- Patients with a HLA matched related or unrelated donor (9\~10/10) or haplo-identical related donor, plan to receive HSCT.
- Age ≤ 60 years old, men and women are not limited.
- The Eastern Oncology Collaborative Group Physical Status Assessment ( ECOG-PS ) was 0-2 points.
- Informed consent must be signed before the start of the study procedure. Informed consent must be signed by the patient or his or her immediate family members who are 18 years of age or older ; informed consent was signed by the legal guardian for children and adolescent patients under 18 years old. Considering the patient 's condition, if the patient 's signature is not conducive to the treatment of the disease, the informed consent is signed by the legal guardian or the patient 's immediate family.
Exclusion criteria
- Have a history of cancer and have received any treatment for this tumor in the past 3 years. But remove superficial bladder cancer, skin basal cells or squamous cell carcinoma, cervical epithelium. Intraepithelial neoplasia ( CIN ) or prostatic intraepithelial neoplasia ( PIN ).
- MPAL.
- It is known that the serological reaction of HIV or active hepatitis C virus is positive.
- The inability to cooperate with the requirements of research, treatment and monitoring due to mental illness or other conditions.
- Pregnant patients or patients who could not take appropriate contraceptive measures during treatment.
- Previously received hematopoietic stem cell transplantation.
- Active heart disease, defined as one or more of the following :
- ) Uncontrolled or symptomatic angina history.
- ) Myocardial infarction less than 6 months away from the study.
- ) Have a history of arrhythmia requiring drug treatment or severe clinical symptoms.
- ) Uncontrolled or symptomatic congestive heart failure ( > NYHA class 2 ).
- ) The ejection fraction is lower than the lower limit of the normal range.
- Researchers evaluated that is not suitable for the group.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06133556 · IIT2023023-EC-2